Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
What does it do?
Omnicell makes the machines and software that hospitals use to store and dispense medications safely. Think of it like a smart vending machine for drugs — nurses tap in, grab the right medication, and the system tracks every single pill. This prevents theft, reduces errors, and speeds up care. Their hardware sits in hospital hallways and pharmacies across the US and internationally.
Hospitals are under enormous pressure to cut costs and reduce medication errors, which kill tens of thousands of patients annually in the US alone. Omnicell sits at the intersection of automation and healthcare, two of the most powerful spending trends right now. As health systems look to do more with fewer staff — a crisis that exploded post-pandemic — automated pharmacy solutions become less of a nice-to-have and more of a necessity.
How does it make money?
Omnicell generates revenue in two main ways: selling hardware like its Titan XT automated dispensing cabinets, and charging recurring subscription and service fees for software and support. Revenue grew from $1.1B to $1.2B year-over-year, roughly a 9% increase. The company has been pushing hard toward a SaaS model — that means more predictable, subscription-based income rather than one-off equipment sales. Net income is essentially zero right now, meaning the company is roughly breaking even.
Why do investors care?
The growth story is the shift from selling boxes to selling ongoing services — recurring revenue is more valuable to investors because it is predictable and sticky, meaning hospitals rarely rip out systems they depend on daily. If Omnicell can convert its large installed base of hardware customers into long-term software subscribers, margins could expand significantly. What has to go right: hospital IT budgets need to keep flowing, and Omnicell needs to execute on this transition without losing customers to rivals.
Deep Dive
MemberA full investor briefing on Omnicell, Inc. — history, leadership, risks, and outlook.